POLTECHDTPA 13.25MG/VIAL POWDER FOR INJECTION

Land: Kypros

Språk: gresk

Kilde: Φαρμακευτικών Υπηρεσιών του Υπουργείου Υγείας

Aktiv ingrediens:

SODIUM DIETHYLENETRIAMINE PENTAACETATE MONOHYDRATE

Tilgjengelig fra:

NATIONAL CENTRE FOR NUCLEAR RESEARCH (0000009483) ANDRZEJA SOLTANA STR. 7, OTWOCK, 05-400

ATC-kode:

V09CA01

INN (International Name):

TECHNETIUM (99MTC) PENTETIC ACID

Dosering :

13.25MG/VIAL

Legemiddelform:

POWDER FOR INJECTION

Sammensetning:

SODIUM DIETHYLENETRIAMINE PENTAACETATE MONOHYDRATE (8000004678) 13,25MG

Administreringsrute:

INTRAVENOUS USE

Resept typen:

Ειδική άδεια άρθρο 126A

Terapeutisk område:

TECHNETIUM (99mTc) PENTETIC ACID

Produkt oppsummering:

Νομικό καθεστώς: Με Ιατρική Συνταγή; PACK WITH 6 VIALS () 6 VIAL - Εγκεκριμένο - Με Ιατρική Συνταγή

Informasjon til brukeren

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
POLTECHDTPA, 13.25 MG, KIT FOR RADIOPHARMACEUTICAL PREPARATION
Sodium diethylenetriaminepentaacetate monohydrate (DTPA)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU ARE GIVEN THIS MEDICINE
BECAUSE IT CONTAINS IMPORTANT
INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your referring doctor or your
nuclear medicine doctor who will
supervise the procedure.
-
If you get any side effects, talk to your nuclear medicine doctor.
This includes any possible side
effects not listed in this leaflet.
WHAT IS IN THIS LEAFLET
1.
What PoltechDTPA is and what it is used for
2.
What you need to know before PoltechDTPA is used
3.
How PoltechDTPA is used
4.
Possible side effects
5.
How PoltechDTPA is stored
6.
Contents of the pack and other information
1.
WHAT POLTECHDTPA IS AND WHAT IT IS USED FOR
This medicine is a radiopharmaceutical product for diagnostic use
only.
PoltechDTPA after labelling with radioactive isotope of technetium (
99m
Tc) is used for renal
scintigraphic imaging (dynamic renal scintigraphy for GFR measurement
of each kidney and
evaluation of urinary flow disorders), GFR measurement from the plasma
samples, and for the
cerebral angiography and brain scanning.
The use of PoltechDTPA does involve exposure to small amounts of
radioactivity. Your doctor and
the nuclear medicine doctor have considered that the clinical benefit
that you will obtain from the
procedure with the radiopharmaceutical outweighs the risk due to
radiation.
2.
WHAT YOU NEED TO KNOW BEFORE POLTECHDTPA IS USED
POLTECHDTPA MUST NOT BE USED
PoltechDTPA must not be used if you are allergic to the active
substance or any of the other
ingredients of this medicine (listed in section 6).
WARNINGS AND PRECAUTIONS
Take special care with PoltechDTPA
-
If you have reduced kidney function,
-
if you are pregnant or believe you may be pregnant,
-
if you are breastfeeding.
The administration of radiopharmaceuticals creates risks for other
persons from